While it is clear that the proteasome is the major player in degradative proteolysis in the nucleus and cytosol, there is a lack of complete agreement on whether there are alternative proteolytic pathways or activities responsible for a significant degradation of cytosolic/nuclear substrates. Particularly relevant is the case of the aminopeptidase TPPII (tripeptidyl peptidase II), which has been suggested to be able to perform some of the proteasome functions. However, the current evidence seems to support only a limited role for these cytosolic alternatives. On the other hand, there is evidence of an alternative, autophagy, a pathway involving the delivery of cytosolic substrates to the lysosome for degradation.
Introduction
It is a well-established fact that the proteasome is the main culprit for protein turnover in the nucleus and the cytosol. The proteasome is a large, multicatalytic protease, very abundant both in the nucleus and the cytosol, which degrades proteins in a finely regulated fashion. Its catalytic core, the 20S proteasome, is composed of four heptameric rings; the two central rings, composed of β-subunits, bear the catalytic activity, whereas the outer rings, made of α-subunits, are the substrates of the regulation of access to the catalytic groups. This access is regulated either by the 19S regulatory particle or by PA28. The former confers the ATP-and ubiquitindependency of proteolysis [1] , whereas the role of the latter is more obscure, although this is beginning to be convincingly addressed, and it participates in the degradation of certain substrates in a ubiquitin-and ATP-independent fashion [2] .
While there is little doubt about the essential role of the proteasome in cellular proteolysis, there is a debate regarding the existence of proteolytic pathways alternative to the UPS (ubiquitin-proteasome system). Evidence in support of the presence of these pathways stems from two main areas: the study of the degradation of individual substrates of degradative proteolysis and work on proteasome dependency of antigen presentation by MHC class I. In both cases, much of the work relies on the use of inhibitors that target different proteolytic activities.
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the cell is synthesizing at a given moment, and this is what the CD8 + T-lymphocytes use to spot which cells are, for example, infected by viruses, at the same time ignoring others that are not. The large amount of evidence accumulated so far has established a correlation between degradative pathways in the cytosol and the sources of MHC class I ligands.
Evidence supporting alternative pathways in the nucleus/cytosol: studies of individual substrates
The appearance of proteasome inhibitors in the field of proteolysis came to show its crucial role in multiple processes, not the least MHC class I antigen processing [4] . But this also brought multiple exceptions, both in protein turnover and in antigen presentation.
Thus examples of degradation of different substrates that were resistant to proteasome inhibitors have been reported. However, in most instances there is no or very little information about the proteolytic activities responsible, this coming most of the time from general protease inhibitors. Furthermore, some of those results have been re-evaluated in the light of new evidence.
Human cytomegalovirus was reported to stabilize p53 through decreased ubiquitination, mediated by a proteasomeindependent degradation of HMD2 [5] . However, work from other groups found that this step was sensitive to proteasome inhibitors and therefore proteasome-dependent [6] . Another instance in which interpretation of results obtained with proteasome inhibitors is not straightforward is the regulation of p21 CIP1/WAF1 induced by iron depletion. The inability of MG-132 (the proteasome inhibitor carbobenzoxy-Lleucyl-L-leucyl-leucinal) to prevent the down-regulation of the cyclin-dependent kinase inhibitor was not due to proteasome-independent degradation, but due to a decrease in translation induced by the chelator used to deplete iron [7] .
Examples of proteases that have been suggested to play a role in proteolysis include calpains, which have been implicated in the regulated degradation of β-catenin in a proteasome-independent manner, by showing that this degradation was sensitive to interference with calpain function but only partially resistant to proteasome inhibition with lactacystin [8] . However, there is evidence that calpain may be acting upstream the UPS [9] , and this could explain the previous results, if a previous calpain-dependent step was required for UPS targeting of β-catenin. Also calpain 3 cleaves cyclin A, removing the N-terminal destruction box, and thus preventing its proteolytic degradation [10] .
Another recent example involves caspases, shown to play a role in the TNFα (tumour necrosis factor α)-induced degradation of Mcl-1 in neutrophils [11] . A different case is that of TPPII (tripeptidyl peptidase II), which we will deal with below.
In summary, it seems that there may be some nuclear/ cytosolic non-proteasomal proteolytic routes, but they do not seem to be of general relevance, and may apply only to a restricted number of substrates. Given that most of the proteases studied do not degrade substrates either to free amino acids or small peptides, which would be substrates of oligopeptidases, it is possible that small proteins, or small fragments of a larger protein, would bypass the requirement for proteasome activity, by generating products small enough to be substrates for oligo-and amino-peptidases.
Evidence supporting alternative pathways in the nucleus/cytosol: studies of MHC class I antigen processing
The fact the ligand binding to class I molecules takes place only in the lumen of the ER (endoplasmic reticulum), and that it relies on the ER-resident peptide transporter TAP, leads to the conclusion that the source of precursors of this pathway derive from proteolysis in the cytosol. There is a significant amount of reports showing some proteasome independence of peptide presentation [12] . Examples of proteasomeinhibitor-resistant ligands include epitopes whose presentation is not only not inhibited, but in fact enhanced by inhibition of the proteasome. In one of these examples, it was also shown that when an unstable form of the donor protein (degraded through the N-end rule) was stabilized by proteasome inhibitors, the presentation of the peptide was not compromised [13] . However, a recent re-evaluation of this epitope suggested that presentation is proteasome dependent [14] (see below). Another intriguing example recently reported deals with the nature of the donor proteins of such peptides; in a study aiming at the identification of 'proteasome-independent' HLA-B27 ligands it was shown that these belonged to a restricted set of proteins in the proteome: small, basic proteins [15] . The fact that they are small may indeed be compatible with the possibility of by-passing the proteasome, as outlined above.
Proteasome inhibitors: drawbacks and some advantages
The use of proteasome inhibitors poses serious challenges in the interpretation of results, some of them shared with other types of inhibitors. First, and most obvious, are the offtarget effects of the inhibitors; one rule that would apply is that a chemical inhibitor is specific for its target only until other targets are found, which almost always happens. Secondly is the fact that they are not 100 % effective with the three proteasome activities, resulting in the proteasome still being able to degrade substrates. This would of course affect substrates differently, posing a serious problem to the validity of the positive controls used as a 'proteasome-dependent' contrast to the 'proteasome-independent' degradation substrate. Therefore one should use extreme caution when assessing proteasome independence. This has indeed been shown to happen with purified 26S proteasomes: different proteasome inhibitors affected differently the degradation of different protein substrates [16] . In line with these observations are the results that re-evaluate the 'proteasome-independence' of the presentation of a peptide by MHC class I whose efficiency was enhanced by proteasome inhibitors. Analysis of the products of in vitro digestions with purified 20S proteasomes of extended peptides showed that lactacystin-treated proteasomes yielded peptides compatible with the antigen-processing pathway, whereas the non-treated proteasomes efficiently destroyed the antigenic peptide [14] . Thirdly are the effects of proteasome inhibitors on cells after prolonged periods of incubation. The response will vary with the cell being studied, but essentially no cell will remain unresponsive to the inhibition of their proteasomes, and large alterations in protein expression have been reported after periods as short as 4-6 h. Pre-incubations with inhibitors should therefore be reduced to the minimum possible to allow for the highest efficiency of inhibition.
The advantage of the use of inhibitors over the usually preferred interference with expression, besides the obvious harmful effect of long term lack of proteasome activity, is their speed of action. This prevents the adaptation of cells to a reduced proteasome activity, and the development of other routes, not necessarily proteolytic, of handling the accumulated substrates.
The case of TPPII
In 1998, it was reported that some cell lines could be adapted to grow in the presence of proteasome inhibitors. This was correlated with the up-regulation of an AAF-cmk (Ala-AlaPhe-chloromethane)-sensitive proteolytic activity which was not identified at the time [17] . A year later, this activity was identified as TPPII; furthermore, this report identified a yet poorly characterized endopeptidase activity of this peptidase [18] . In 2001, it was shown that there was no need to select with proteasome inhibitors to get cells with similar characteristics: Burkitt's lymphoma cells had a reduced proteasome activity, and increased levels and activity of TPPII, compared with EBV (Epstein-Barr virus)-transformed lymphoblastoid cell lines [19] . These authors also found increased activity of deubiquitinating enzymes, with some of the up-regulated enzymes identified in later reports [20] . Landmarks of these studies were a decreased sensitivity to proteasome inhibitors and an increased sensitivity to AAF-cmk, both in terms of cell viability and of accumulation of ubiquitinated substrates [17, 19, [21] [22] [23] .
Evidence from the antigen processing field seemed to support this model: a proteasome-independent (or proteasome-inhibitor-resistant) MHC class I ligand from HIV-Nef required TPPII activity for its presentation [24] ; similar results were obtained for an influenza virus NP (nucleoprotein)-derived ligand [25] , although another report did not find the TPPII requirement [14] .
However, this model is not without problems. In fact it was shown that the adapted cells still require proteasome activity for survival [22] . Also from the antigen processing, as mentioned above, Wherry et al. [14] presented evidence that lactacystin-treated proteasomes were still active and could indeed be more efficient for the antigen processing route. This probably means that the TPPII requirement lies downstream of the proteasome, as has been suggested [26, 27] . This agrees with the fact that proteasome-inhibitor-treated purified proteasomes can still digest substrate proteins, with different results depending on the model substrate and on the activities affected by the inhibitor [16] . One of the main conclusions of this work is that, to block the UPS completely, all three activities must be inhibited; otherwise the proteasomes will retain the ability to degrade proteins, albeit with quantitative and qualitative differences. If one takes into consideration that proteasome inhibitors will not block efficiently the three activities, it follows that, under most of the conditions used in the literature, substantial proteasome activity still remains. Thus it is likely that the effects of AAF-cmk on cells are not due to inhibition of TPPII (E.M. Villasevil, S. Guil, C. Sánchez, M. Del Val and L.C. Antón, unpublished work).
Autophagy
The term autophagy includes a group of different pathways that lead to lysosomal degradation of cytoplasmic material. CMA (chaperone-mediated autophagy) and macroautophagy are the most studied, and probably the most relevant, in mammalian systems; they may constitute significant contributors to the degradation of cytosolic proteins, supported by the demonstration of their roles in presentation of MHC class II ligands derived from cytosolic proteins [28] . MHC class II, as opposed to class I, binds peptides in a specialized late endosome/lysosome. In CMA, substrates bind to Hsc70 (heat-shock cognate 70 stress protein), are transported to the lysosome through binding to LAMP-2A (lysosome-associated membrane protein-2A), unfolded and translocated to the lysosomal lumen; this pathway relies on a specific sequence on the target protein, related to the canonical KFERQ [29] . The contribution of macroautophagy to protein (and organelle) turnover, particularly during nutrient deprivation, is well established [30] ; this situation is most dramatic in the perinatal period, when a genetic deficiency in macroautophagy in mice is lethal [31] . On the other hand, its constitutive activity plays a crucial role in maintaining fully efficient proteolysis, as mice with tissue-specific disruption of macroautophagy show neurodegeneration or liver damage, with ubiquitin-containing inclusions [32] . These studies have confirmed the crucial role of this pathway in the handling of Ub + aggregates [33] . It was also shown that prolonged incubations with proteasome inhibitors induce autophagy [34] , and the autophagic vesicles tend to accumulate near the aggresomes formed around the centrosomes [34, 35] .
Concluding remarks
The field of proteasome-independent degradative proteolysis of cytosolic substrates is still an open question, although its significance as a general mechanism may be restricted to a group of pathways, autophagy, or to a number of substrates. These pathways are still relevant to antigen processing, as the function of T-cells relies on the recognition of individual peptides associated with MHC class I; if one of the relevant peptides in an immune response is presented in a proteasome-independent manner, then this proteolytic pathway will be of great significance. Therefore establishing the role of autophagy and other proteolytic routes, no matter how minor, is still of major importance. 
